The trial met its primary and secondary endpoints demonstrating that administration of a 3-dose regimen of GARDASIL 9
The collaborations will help curate industry focused courses such as Advanced Certification courses for healthcare professionals in Healthcare Marketing, Healthcare Technology and Specialized Clinical Fellowship Level programs with university accreditation
MedTech Mitra initiative aims to empower MedTech innovators and advance healthcare solutions
This case is an isolated case, similar to the earlier 30 cases reported in India from July 2022 onwards
TROPION-Lung01, evaluating AstraZeneca and Daiichi Sankyo’s datopotamab deruxtecan versus chemotherapy, previously met the dual primary endpoint of progression-free survival in the overall trial population
The study observed 2,648 girls, of which 2,300 completed the standard 45-day programme
Objective response rate of 54.8% seen with Daiichi Sankyo and Merck’s ifinatamab deruxtecan at 12 mg/kg dose in pretreated patients
Transform healthcare by integrating expertise from AI, clinical sciences, and basic sciences to harness India’s extensive data sets for improving the access to healthcare
This Fast Track Designation will enable FDA to review MM-II in an expedited manner, is an important milestone in the development of MM-II
Phase 3 clinical trial designed to evaluate the safety and efficacy of tivozanib in combination with nivolumab
Subscribe To Our Newsletter & Stay Updated
